Could There Be a Non-Vaccine COVID Cure?
Former FDA Commisssioner Scott Gottlieb, a member of Pfizer’s board of directors, updates Molly Jong-Fast on the status of “COVID pills” and child-approved jabs in the works.

Photo Illustration by The Daily Beast/Getty
There could be another line of defense against COVID-19 on the medical horizon—one that doesn’t involve taking horse medication or even vaccine boosters.
According to Scott Gottlieb, author of Uncontrolled Spread, former FDA commissioner, and a member of Pfizer’s board of directors, there are three promising pills in development to help treat COVID like “Tamiflu for influenza,” he tells Molly Jong-Fast on the latest episode of The New Abnormal. Of course, vaccines are the best way to slow the spread of COVID-19 and prevent serious infection and hospitalization, but the more protection, the better.
Subscribe to The New Abnormal on Apple Podcasts, Spotify, Google Podcasts, Stitcher, Amazon Music, or Overcast. To listen to our weekly members-only bonus episodes, join Beast Inside here. Already a member? You can listen here and sign up for new episode email alerts here.
“So if you’re exposed to COVID, you could take a pill and it can prevent you or reduce your chances of getting COVID,” explains Gottlieb. “There are three that are in more advanced development: a drug by Pfizer, in phase three studies, a drug by Merck, which looks very promising, also in phase three studies, and another one by Roche that’s a little further behind any one of these drugs.”
It sounds great, but we still have to deal with the surging Delta variant, and that means getting more people, and kids, vaccinated. When is that going to happen? Molly wants to know. Gottlieb projects later this fall. He also doesn’t think we should be too invested in the Biden administration sending vaccines overseas.
Get the best of The Beast delivered right to your inbox
By clicking “SUBSCRIBE” you agree to our Terms of Use and Privacy Policy.
“They’re going to want to hedge against the unknown, you know, a new variant coming alongside the population. So as a matter of national security, the doses that have been secured by the administration are going to be kept by the administration.”
Eric Boehlert, founder and editor of PressRun.media, also joins the show to discuss how the media covered Trump voters compared to how they cover President Joe Biden’s.
“The press, you know, they beat themselves up after Trump won; they felt like they missed the story. And so they went on to do these orgies of Trump voter stories,” Boehlert explains. “So now we have a Democrat. Why don’t you, like, return the favor? Why aren’t we constantly getting updates and hearing the voices of people of color, as well as everyone else who gave 80 million votes?”
Plus! Emily Ramshaw of The 19th News paints a grim picture of the “abortion tourism” set to ramp up in states around Texas.
Listen to The New Abnormal on Apple Podcasts, Spotify, Amazon and Stitcher.
Unlock a year of full access to The Looker and The Daily Beast for $35.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.
Register below to read this article for free or subscribe
to unlock unlimited access to The Looker and The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.
Sign in
Login dialog


